Abstract
Background: High expression of glucagon-like peptide-1 receptor (GLP-1R) in insulinoma supplies a potential drug target for tumor imaging. Exendin-4 can specifically bind to GLP-1R as an agonist and its analogs are extensively used in receptor imaging studies.
Purpose: A new GLP-1R imaging agent, [18F]AlF-NOTA-MAL-Cys39-exendin-4, was designed and prepared for insulinoma imaging.
Methods: Cys39-exendin-4 was conjugated with NOTA-MAL, then the compound was radiolabeled with [18F]AlF complex to obtained [18F]AlF-NOTA-MAL-Cys39-exendin-4. The tumor-targeting characters of the tracer were evaluated in INS-1 cells and BALB/c nude mice models.
Results: [18F]AlF-NOTA-MAL-Cys39-exendin-4 can be efficiently produced with a yield of 17.5 ± 3.2% (non-decay corrected) and radiochemical purity of >95%. The IC50 value of displacement [18F]AlF-NOTA-MAL-Cys39-exendin-4 with Cys39-exendin-4 was 13.52 ± 1.36 nM. PET images showed excellent tumor visualization with high uptake (9.15 ± 1.6%ID/g at 30 min and 7.74 ± 0.87%ID/g at 60 min). The tumor to muscle, pancreas and liver ratios were 63.25, 3.85 and 7.29 at 60 min after injection. GLP-1R binding specificity was demonstrated by co-injection with an excess of unlabeled Cys39-exendin-4 and the tumor uptake was found to be reduced significantly.
Conclusion: [18F]AlF-NOTA-MAL-Cys39-exendin-4 shows favorable characteristics for insulinoma imaging and may be translated to clinical studies.
Declaration of interest
This work was supported by National Significant New Drugs Creation Program (2012ZX09505-001-001), National Natural Science Foundation (81171399, 51473071, 81101077, 21401084, 81401450 and 81472749), Jiangsu Province Foundation (BK2011166, BE2014609, BE2012622, BL2012031 and BM2012066), Outstanding Professional Fund of Health Ministry in Jiangsu Province (RC2011095 and Q201406) and Wuxi Foundation (CSZ0N1320).